CClinicalTrials.gg
RecruitingNCT07312461HMUPUpdated Dec 31, 2025

Causes and Management of Children Presenting With Macroscopic Hematuria in the Pediatric Emergency Department

An observational study in Macroscopic Hematuria, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
Up to 17 Years
Sex
All
01

Study summary

Macroscopic hematuria. is a common symptom, leading to numerous emergency department visits in children of all ages.

It can be linked to many pathologies, and its management in the emergency department is not standardized.

Few articles describe the management of this symptom during pediatric emergency department visits.

Therefore, it is important to study this symptom and its management in order to establish a protocol.

02

Conditions studied

  • Macroscopic Hematuria

Keywords

  • Macroscopic hematuria
  • Hematuria in children
03

In context

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Minor subject (\<18 years old) presenting to the pediatric emergency department with gross hematuria

Inclusion criteria

  • Minor subject (\<18 years old)
  • Patient presenting to the pediatric emergency department with gross hematuria

Exclusion criteria

Exclusion Criteria:

- Subject (and/or their parents) who expressed their opposition to participating in the study.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Describe the different causes of this symptom

    Time frame: Up to 12 months

07

Study locations

1 of 1 sites recruiting
  • Service de Pédiatrie 1 - Réanimation - CHU de Strasbourg - France
    Strasbourg, 67091, France
    • Ariane ZALOSZYC, MD, PhD · Contact · ariane.zaloszyc@chru-strasbourg.fr · 33 3 88 12 77 42
    • Ariane ZALOSZYC, MD, PhD · Principal investigator
    • Inès BERNHARD, MD · Principal investigator
    • Sarah DE THOMASIS, MD · Principal investigator
    • Noelle LACHAUSSEE, MD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07312461
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Sep 30, 2024
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

Ariane ZALOSZYC, MD
Contact
ariane.zaloszyc@chru-strasbourg.fr
33 3 88 12 77 42

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion